Spyglass Pharma
NASDAQ: SGP2 known investors
SpyGlass Pharma develops a sustained drug delivery system, the BIM-IOL System, that integrates long-acting glaucoma therapy into cataract surgery. The technology is aimed at ophthalmic care for patients with chronic eye disease such as glaucoma.